Ipsen SA
39.9 FTEThe score of Ipsen shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +22 % Equity +12 % Total assets +8 % Headcount (avg FTE) +1 %
Accounts of the company itself (not consolidated).
The full file covers 14 financial years; a free account shows 2. →Ipsen's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €71.3m | ||||
| Net result | €4.17m | ||||
| Equity | €119.9m | ||||
| Cash | 252 € | ||||
| EBITDA | €3.45m | ||||
| Total assets | €134.4m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jul 2026
- Year ended 31 Dec 2024filed on 11 Jun 2025
- Year ended 31 Dec 2023filed on 04 Jun 2024
- Year ended 31 Dec 2022filed on 09 May 2023
- Year ended 31 Dec 2021filed on 18 May 2022
Ipsen's financial analysis
- Solvency89.2%sector median: 41.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Ipsen
Ipsen's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0422.650.477
- VAT number
- BE0422650477
- Peppol
- Registered · 0208:0422650477 · as of 27 Oct 2026
- Legal form
- SA
- Incorporated
- 09 Apr 1982
- Registered office
- 1000 Brussels
- Size
- Small · 39.9 FTE
- Latest accounts
- 2025 · filed on 17 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Ipsen (SA) has been based in Brussels since 1982, active in: manufacture of medicaments. For 2025, it reports revenue of €71.3m, a net profit of €4.17m and equity of €119.9m. With 39.9 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 89.2%, above the median of its sector (41.4%).
Companies similar to Ipsen
Companies in the same business, of comparable size and area, outside its group.
- Pfizer Manufacture of pharmaceutical preparations Ixelles · balance sheet €377.4m
- Novo Nordisk Production Belgium SA Manufacture of pharmaceutical preparations Brussels · balance sheet €153.5m
- JNTL Consumer Health (Belgium) Manufacture of basic pharmaceutical products Antwerp · balance sheet €156.0m
- Tilman Manufacture of pharmaceutical preparations Somme-Leuze · balance sheet €43.2m
- Baxter Manufacture of pharmaceutical preparations Lessines · balance sheet €160.0m
- Organon Heist Manufacture of pharmaceutical preparations Heist-op-den-Berg · balance sheet €349.6m
- Novartis Manufacturing Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €285.2m
- Alcon Laboratories Belgium Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €107.2m
Frequently asked questions about Ipsen
What is the revenue of Ipsen?
According to the 2025 annual accounts filed with the NBB, the revenue of Ipsen amounts to 71,316,801 €.
What is the VAT number of Ipsen?
In Belgium, the VAT number is the company number prefixed with BE: BE0422650477 for Ipsen, if the company is VAT-registered. Its company number (CBE) is 0422.650.477.
Where is the registered office of Ipsen?
According to the CBE register, the registered office of Ipsen is in 1000 Brussels.
What is the equity of Ipsen?
At the close of the 2025 financial year, the equity of Ipsen amounts to 119,884,487 €, a solvency of 89.2% of total assets.
How many people work at Ipsen?
39.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Ipsen?
The register lists 3 active mandates at Ipsen. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Ipsen
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →